* the absence of attending or referring physician * any sign of seriousness incompatible with home care. * severe chronic kidney failure or dialysis (i.e. dfge \<30). * drink cure contraindication (500 ml/d for 21 days). * contraindication to any drug in the study, including a known allergy, especially magnesium. * uncontrolled and clinically significant heart disease, whether its origin (arrhythmias, angina, uncompensated congestive heart failure). * subject participating to an other clinical study interventional. * person deprived of liberty or under legal guardianship. * no one in the same household who participated in this study. * patient refusing hospitalization. * persons subject to sections l1121-7 and l1121-8 of the csp (minor, person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure) or not able to communicate his consent verbally.

* the absence of attending or referring physician * any sign of seriousness incompatible with home care. * severe chronic kidney failure or dialysis (i.e. dfge \<30). * drink cure contraindication (500 ml/d for 21 days). * contraindication to any drug in the study, including a known allergy, especially magnesium. * uncontrolled and clinically significant heart disease, whether its origin (arrhythmias, angina, uncompensated congestive heart failure). * subject participating to an other clinical study interventional. * person deprived of liberty or under legal guardianship. * no one in the same household who participated in this study. * patient refusing hospitalization. * persons subject to sections l1121-7 and l1121-8 of the csp (minor, person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure) or not able to communicate his consent verbally.

- the absence of attending or referring physician - any sign of seriousness incompatible with home care. - severe chronic kidney failure or dialysis (i.e. dfge <30). - drink cure contraindication (500 ml/d for 21 days). - contraindication to any drug in the study, including a known allergy, especially magnesium. - uncontrolled and clinically significant heart disease, whether its origin (arrhythmias, angina, uncompensated congestive heart failure). - subject participating to an other clinical study interventional. - person deprived of liberty or under legal guardianship. - no one in the same household who participated in this study. - patient refusing hospitalization. - persons subject to sections l1121-7 and l1121-8 of the csp (minor, person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure) or not able to communicate his consent verbally.

- the absence of attending or referring physician - any sign of seriousness incompatible with home care. - severe chronic kidney failure or dialysis (i.e. dfge <30). - drink cure contraindication (500 ml/d for 21 days). - contraindication to any drug in the study, including a known allergy, especially magnesium. - uncontrolled and clinically significant heart disease, whether its origin (arrhythmias, angina, uncompensated congestive heart failure). - subject participating to an other clinical study interventional. - person deprived of liberty or under legal guardianship. - no one in the same household who participated in this study. - patient refusing hospitalization. - persons subject to sections l1121-7 and l1121-8 of the csp (minor, person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure) or not able to communicate his consent verbally.

- the absence of general practitioner. - any sign of seriousness incompatible with home care. - severe chronic kidney failure or dialysis (i.e. dfge <30). - drink cure contraindication (500 ml/d for 21 days). - contraindication to any drug in the study, including a known allergy, especially magnesium. - uncontrolled and clinically significant heart disease, whether its origin (arrhythmias, angina, uncompensated congestive heart failure). - subject participating to an other clinical study interventional. - person deprived of liberty or under legal guardianship. - no one in the same household who participated in this study. - patient refusing hospitalization. - persons subject to sections l1121-7 and l1121-8 of the csp (minor, person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure) or not able to communicate his consent verbally.

- the absence of general practitioner. - any sign of seriousness incompatible with home care. - severe chronic kidney failure or dialysis (i.e. dfge <30). - drink cure contraindication (500 ml/d for 21 days). - contraindication to any drug in the study, including a known allergy, especially magnesium. - uncontrolled and clinically significant heart disease, whether its origin (arrhythmias, angina, uncompensated congestive heart failure). - subject participating to an other clinical study interventional. - person deprived of liberty or under legal guardianship. - no one in the same household who participated in this study. - patient refusing hospitalization. - persons subject to sections l1121-7 and l1121-8 of the csp (minor, person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure) or not able to communicate his consent verbally.